Cancer Research Cell Death Mechanisms and Cancer Therapy  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zipin, A.
Right arrow Articles by Witz, I. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zipin, A.
Right arrow Articles by Witz, I. P.
[Cancer Research 64, 6571-6578, September 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Tumor-Microenvironment Interactions

The Fucose-Generating FX Enzyme Controls Adhesive Properties of Colorectal Cancer Cells

Adi Zipin1, Mira Israeli-Amit1, Tsipi Meshel1, Orit Sagi-Assif1, Ilana Yron1, Veronica Lifshitz1, Eran Bacharach1, Nechama I. Smorodinsky1, Ariel Many2, Peter A. Czernilofsky3, Donald L. Morton4 and Isaac P. Witz1

1 Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel; 2 Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 3 Faculty of Medicine, University of Vienna, Vienna, Austria; and 4 John Wayne Cancer Institute, Santa Monica, California

Extravasation of tumor cells is a pivotal step in metastasis formation. This step is initiated by an interaction of extravasating tumor cells with endothelial cells. Among the molecules mediating tumor-endothelium interactions are selectins and their fucosylated ligands. In a previous study, we demonstrated that the fucose-generating FX enzyme regulates the expression of selectin ligands by B and T lymphocytes and by head and neck squamous cell carcinoma cells. It was also shown that the FX enzyme regulated important interaction parameters between these cancer cells and endothelial cells. The present study was aimed to determine whether the FX enzyme controls adhesive interactions between colorectal cancer cells and endothelial cells. The results clearly indicate that this is indeed the case. Overexpressing the FX enzyme by the transfer of FX cDNA to low FX-expressing colorectal cancer cells resulted in an increased adhesive capacity of the transfectants to activated endothelial cells and to recombinant E-selectin. Down-regulating FX levels in colorectal cancer cells expressing high levels of endogenous FX by transfection with small-interfering RNA resulted in a down-regulated expression of the selectin ligand sialyl Lewis-a and a decrease in the adhesive capacity of the transfectants to activated endothelial cells and to recombinant E-selectin. These transfection experiments also indicated that manipulating the levels of the FX enzyme affected global cellular fucosylation and altered the interaction of colorectal cancer cells with some extracellular matrix components such as fibronectin. We also found that highly metastatic colorectal cancer variants express higher levels of FX and of sialyl Lewis-a than low metastatic variants originating in the same tumors. These results lead us to hypothesize that the FX enzyme controls the capacity of colorectal cancer to extravasate and form metastasis. If this hypothesis will be confirmed the FX enzyme could become a target molecule for metastasis prevention.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. Chen, G. Li, W. Liao, J. Wu, L. Liu, D. Ma, J. Zhou, R. H. Elbekai, M. L. Edin, D. C. Zeldin, et al.
Selective Inhibitors of CYP2J2 Related to Terfenadine Exhibit Strong Activity against Human Cancers in Vitro and in Vivo
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 908 - 918.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
K. Moriwaki, K. Noda, T. Nakagawa, M. Asahi, H. Yoshihara, N. Taniguchi, N. Hayashi, and E. Miyoshi
A High Expression of GDP-Fucose Transporter in Hepatocellular Carcinoma is a Key Factor for Increases in Fucosylation
Glycobiology, December 1, 2007; 17(12): 1311 - 1320.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-G. Jiang, Y.-G. Ning, C. Chen, D. Ma, Z.-J. Liu, S. Yang, J. Zhou, X. Xiao, X. A. Zhang, M. L. Edin, et al.
Cytochrome P450 Epoxygenase Promotes Human Cancer Metastasis
Cancer Res., July 15, 2007; 67(14): 6665 - 6674.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Gout, C. Morin, F. Houle, and J. Huot
Death Receptor-3, a New E-Selectin Counter-Receptor that Confers Migration and Survival Advantages to Colon Carcinoma Cells by Triggering p38 and ERK MAPK Activation.
Cancer Res., September 15, 2006; 66(18): 9117 - 9124.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Handerson, R. Camp, M. Harigopal, D. Rimm, and J. Pawelek
{beta}1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma
Clin. Cancer Res., April 15, 2005; 11(8): 2969 - 2973.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.